CR20120576A - Inhibidores de pirazolil quinazolina cinasa - Google Patents
Inhibidores de pirazolil quinazolina cinasaInfo
- Publication number
- CR20120576A CR20120576A CR20120576A CR20120576A CR20120576A CR 20120576 A CR20120576 A CR 20120576A CR 20120576 A CR20120576 A CR 20120576A CR 20120576 A CR20120576 A CR 20120576A CR 20120576 A CR20120576 A CR 20120576A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pirazolil
- quinazolina
- cinasa
- inhibitors
- cinasa inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32988410P | 2010-04-30 | 2010-04-30 | |
GB201007286A GB201007286D0 (en) | 2010-04-30 | 2010-04-30 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120576A true CR20120576A (es) | 2013-03-04 |
Family
ID=42289929
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180339A CR20180339A (es) | 2010-04-30 | 2011-04-28 | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) |
CR20120576A CR20120576A (es) | 2010-04-30 | 2012-11-13 | Inhibidores de pirazolil quinazolina cinasa |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180339A CR20180339A (es) | 2010-04-30 | 2011-04-28 | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) |
Country Status (35)
Country | Link |
---|---|
US (6) | US8895601B2 (es) |
EP (3) | EP3178818B1 (es) |
JP (1) | JP5639261B2 (es) |
KR (2) | KR101933843B1 (es) |
CN (2) | CN104725362B (es) |
AP (1) | AP3210A (es) |
AR (1) | AR080982A1 (es) |
AU (2) | AU2011247047B2 (es) |
BR (1) | BR112012027509B1 (es) |
CA (1) | CA2796204C (es) |
CL (1) | CL2012003048A1 (es) |
CR (2) | CR20180339A (es) |
CY (2) | CY1121882T1 (es) |
DK (3) | DK3178818T3 (es) |
EA (2) | EA028599B1 (es) |
EC (1) | ECSP12012318A (es) |
ES (3) | ES2899937T3 (es) |
GB (1) | GB201007286D0 (es) |
HR (1) | HRP20211675T1 (es) |
HU (3) | HUE045893T2 (es) |
IL (1) | IL222600A (es) |
IN (1) | IN2012MN02591A (es) |
JO (1) | JO3366B1 (es) |
LT (3) | LT2563775T (es) |
ME (1) | ME01825B (es) |
MX (2) | MX2012012414A (es) |
MY (2) | MY191669A (es) |
NZ (1) | NZ602726A (es) |
PL (3) | PL3178818T3 (es) |
PT (3) | PT2563775T (es) |
RS (3) | RS59196B1 (es) |
SG (2) | SG184966A1 (es) |
SI (3) | SI3590934T1 (es) |
TW (1) | TWI545122B (es) |
WO (1) | WO2011135376A1 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
CA3146333A1 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
PL2421533T3 (pl) | 2009-04-22 | 2019-05-31 | Resverlogix Corp | Nowe środki przeciwzapalne |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
KR102406771B1 (ko) | 2012-06-13 | 2022-06-13 | 인사이트 홀딩스 코포레이션 | Fgfr 억제제로서 치환된 트리사이클릭 화합물 |
KR20200117067A (ko) | 2012-07-11 | 2020-10-13 | 블루프린트 메디신즈 코포레이션 | 섬유아세포 성장인자 수용체의 저해제 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
AU2013333575B2 (en) * | 2012-10-15 | 2015-07-16 | Resverlogix Corp. | Compounds useful in the synthesis of benzamide compounds |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
NZ711376A (en) | 2013-03-15 | 2020-01-31 | Sanofi Sa | Heteroaryl compounds and uses thereof |
JP6576325B2 (ja) * | 2013-03-15 | 2019-09-18 | セルジーン シーエーアール エルエルシー | ヘテロアリール化合物およびそれらの使用 |
EP3318564B1 (en) | 2013-04-19 | 2021-07-28 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
GB201307577D0 (en) * | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
JO3512B1 (ar) * | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
CA2943687C (en) * | 2014-03-26 | 2024-02-13 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
PL3122358T3 (pl) | 2014-03-26 | 2021-06-14 | Astex Therapeutics Ltd. | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu |
CN105017227B (zh) * | 2014-07-08 | 2018-03-09 | 四川百利药业有限责任公司 | N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物 |
AU2015304465B2 (en) | 2014-08-18 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
LT3198033T (lt) * | 2014-09-26 | 2022-05-10 | Janssen Pharmaceutica Nv | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
TWI703984B (zh) * | 2015-04-03 | 2020-09-11 | 英商阿斯特克斯治療有限公司 | 用於癌症治療之fgfr/pd-1組合療法 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
MX2018003563A (es) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | Nuevos compuestos. |
CN105596330B (zh) * | 2015-12-11 | 2018-10-16 | 深圳市坤健创新药物研究院 | 虚拟筛选化合物在制备激酶抑制剂中的应用和药物 |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
EP3523285A4 (en) * | 2016-10-10 | 2020-04-22 | Development Center for Biotechnology | QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
CN111032628A (zh) | 2017-08-21 | 2020-04-17 | 细胞基因公司 | 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺 |
US11661411B2 (en) | 2017-12-01 | 2023-05-30 | Board Of Regents Of The University Of Nebraska | Quinoxaline compounds and uses thereof |
KR20200135945A (ko) | 2018-03-28 | 2020-12-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포 암종 치료제 |
CN112368279B (zh) * | 2018-04-26 | 2024-05-28 | 医药生命融合研究团 | 作为mTOR抑制剂的新化合物及其用途 |
DK3788047T3 (da) | 2018-05-04 | 2024-09-16 | Incyte Corp | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
JOP20210052A1 (ar) | 2018-09-21 | 2021-03-18 | Janssen Pharmaceutica Nv | علاج سرطان الأوعية الصفراوية |
US20220041579A1 (en) * | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN113645974A (zh) | 2019-03-29 | 2021-11-12 | 詹森药业有限公司 | 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 |
JOP20210260A1 (ar) | 2019-03-29 | 2023-01-30 | Janssen Pharmaceutica Nv | مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية |
WO2020208592A1 (en) * | 2019-04-12 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of erdafitinib, its purification and amorphous solid dispersion |
CN111909044A (zh) * | 2019-05-09 | 2020-11-10 | 南京爱德程医药科技有限公司 | 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
AU2020352668A1 (en) | 2019-09-26 | 2022-03-31 | Janssen Pharmaceutica Nv | Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN110790677B (zh) * | 2019-11-05 | 2022-04-29 | 浙江工业大学 | 一种金刚烷甲酰胺类化合物及其制备方法和应用 |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN113024517A (zh) * | 2019-12-09 | 2021-06-25 | 武汉九州钰民医药科技有限公司 | 一种制备厄达替尼的方法 |
CN113024518A (zh) * | 2019-12-09 | 2021-06-25 | 武汉九州钰民医药科技有限公司 | 一种厄达替尼的制备方法 |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20240002365A1 (en) * | 2020-01-17 | 2024-01-04 | Beta Pharma, Inc. | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors |
WO2021160764A1 (en) | 2020-02-12 | 2021-08-19 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
WO2022040111A2 (en) | 2020-08-17 | 2022-02-24 | Teva Pharmaceuticals International Gmbh | Solid state forms of erdafitinib salts and processes for preparation of erdafitinib |
CN112920167B (zh) * | 2020-08-19 | 2022-08-26 | 四川大学华西医院 | 靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂 |
CA3191538A1 (en) | 2020-09-14 | 2022-03-17 | Ademi Elena SANTIAGO-WALKER | Fgfr inhibitor combination therapies |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
EP4340840A1 (en) | 2021-05-19 | 2024-03-27 | JANSSEN Pharmaceutica NV | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN117858872A (zh) | 2021-06-22 | 2024-04-09 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
CA3235311A1 (en) | 2021-10-12 | 2023-04-20 | Taris Biomedical Llc | Erdafitinib formulations and systems for intravesical administration |
KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
WO2023159216A1 (en) * | 2022-02-18 | 2023-08-24 | Taris Biomedical Llc | Erdafitinib formulations and osmotic systems for intravesical administration |
CN115108926B (zh) * | 2022-04-02 | 2023-06-20 | 上海工程技术大学 | 一种用于制备厄达替尼的中间体化合物及制备方法 |
WO2024173377A1 (en) | 2023-02-13 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
WO2024170495A1 (en) | 2023-02-13 | 2024-08-22 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
JPH09500615A (ja) | 1993-05-14 | 1997-01-21 | ジェネンテク,インコーポレイテッド | Ras−ファルネシル転移酵素阻害剤 |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
CA2262403C (en) | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
ATE493389T1 (de) | 1997-05-28 | 2011-01-15 | Aventis Pharma Inc | Chinoxalin-derivate die den von blutplättchen abstammenden wachstumsfaktor und/oder p56lck- tyrosinkinase hemmen |
US6235740B1 (en) | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
EA005287B1 (ru) | 1999-09-15 | 2004-12-30 | Уорнер-Ламберт Компани | Птеридиноны в качестве ингибиторов киназ |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
CA2469813C (en) | 2001-12-18 | 2009-02-24 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
KR101029281B1 (ko) | 2001-12-24 | 2011-04-18 | 아스트라제네카 아베 | 오로라 키나제의 억제제로서 치환된 퀴나졸린 유도체 |
JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
US7265378B2 (en) | 2002-07-10 | 2007-09-04 | E. I. Du Pont De Nemours And Company | Electronic devices made with electron transport and/or anti-quenching layers |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
KR20050056227A (ko) | 2002-10-03 | 2005-06-14 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
PT1636228E (pt) | 2003-05-23 | 2009-02-02 | Aeterna Zentaris Gmbh | Novas piridopirazinas e sua utilização como moduladores de cinases |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
EP1646383A4 (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF LIGANDS OPTIMIZED FOR PPAR |
AU2004261667A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against Flaviviridae |
AU2004283479A1 (en) | 2003-10-17 | 2005-05-06 | 4 Aza Bioscience Nv | Heterocycle-substituted pteridine derivatives and their use in therapy |
AU2004288709B2 (en) | 2003-11-07 | 2011-01-06 | Novartis Vaccines And Diagnostics, Inc. | Methods for synthesizing quinolinone compounds |
MXPA06005687A (es) | 2003-11-20 | 2006-08-17 | Janssen Pharmaceutica Nv | 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa. |
CA2545992A1 (en) | 2003-11-24 | 2005-06-16 | F. Hoffmann-La Roche Ag | Pyrazolyl and imidazolyl pyrimidines |
JP4928949B2 (ja) * | 2003-12-23 | 2012-05-09 | アステックス、セラピューティックス、リミテッド | タンパク質キナーゼモジュレーターとしてのピラゾール誘導体 |
US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
AU2005278959A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-Raf inhibitors |
BRPI0516488A (pt) | 2004-10-14 | 2008-09-09 | Hoffmann La Roche | azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1 |
MX2007004480A (es) | 2004-10-15 | 2007-05-08 | Astrazeneca Ab | Quinoxalinas como inhibidores b raf. |
DK1830869T3 (da) | 2004-12-24 | 2013-08-26 | Spinifex Pharm Pty Ltd | Fremgangsmåde til behandling eller profylakse |
NZ556686A (en) | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
WO2006124354A2 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2008540667A (ja) | 2005-05-18 | 2008-11-20 | ワイス | Tpl2キナーゼの4,6−ジアミノ−[1,7]ナフチリジン−3−カルボニトリル阻害物質ならびにそれを製造および使用する方法 |
GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
ZA200801822B (en) | 2005-08-26 | 2009-09-30 | Serono Lab | Pyrazine derivatives and use as p13k inhibitors |
JP5527972B2 (ja) | 2005-11-11 | 2014-06-25 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用 |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
MY159523A (en) | 2005-12-21 | 2017-01-13 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
ATE549338T1 (de) | 2006-05-24 | 2012-03-15 | Boehringer Ingelheim Int | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
JP5244118B2 (ja) | 2006-11-10 | 2013-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | 新規キナーゼ阻害剤 |
JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | 1,5−ナフチリジン化合物及び有機発光素子 |
WO2008076278A2 (en) | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of cancer treatment with igf1r inhibitors |
RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
AR064491A1 (es) * | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
WO2008141065A1 (en) * | 2007-05-10 | 2008-11-20 | Smithkline Beecham Corporation | Quinoxaline derivatives as p13 kinase inhibitors |
EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害剤としてのナフチリジン誘導体 |
AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
CN101784520B (zh) | 2007-06-20 | 2014-07-02 | 田边三菱制药株式会社 | 磺酰基丙二酰胺衍生物和其药物用途 |
WO2008155378A1 (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
EP2173338A1 (en) | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
EP2188292B1 (en) | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
EP2173354A4 (en) * | 2007-08-09 | 2011-10-05 | Glaxosmithkline Llc | CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS |
US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
CN101910152B (zh) | 2007-11-16 | 2014-08-06 | 因塞特公司 | 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺 |
MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
NZ588511A (en) | 2008-05-23 | 2012-04-27 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
WO2010059771A1 (en) | 2008-11-20 | 2010-05-27 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-b]-pyridines and-pyrazines |
US8716280B2 (en) | 2009-01-21 | 2014-05-06 | Basilea Pharmaceutica Ag | Bicyclic antibiotics |
US20110288090A1 (en) | 2009-02-02 | 2011-11-24 | Armstrong Donna J | Inhibitors of AKT Activity |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
ES2940885T3 (es) | 2009-06-12 | 2023-05-12 | Abivax | Compuestos útiles para tratar el envejecimiento prematuro y en particular la progeria |
HUE024874T2 (en) | 2009-09-03 | 2016-02-29 | Bioenergenix | Heterocyclic compounds for inhibiting PASK |
CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途 |
AP2013007043A0 (en) | 2011-01-31 | 2013-08-31 | Novartis Ag | Novel heterocyclic derivatives |
US20140037642A1 (en) | 2011-02-02 | 2014-02-06 | Amgen Inc. | Methods and compositions relating to inhibition of igf-1r |
CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
AU2012300317B2 (en) | 2011-08-26 | 2016-12-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN104080455B (zh) | 2011-09-14 | 2018-07-31 | 润新生物公司 | 某些化学实体、组合物及方法 |
EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
BR112014009890A2 (pt) | 2011-10-28 | 2020-10-27 | Novartis Ag | derivados de purina e seu uso no tratamento de doença |
JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
MX365214B (es) | 2012-03-08 | 2019-05-27 | Astellas Pharma Inc | Nuevo producto de fusion de fgfr3. |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
EP3027623A4 (en) | 2013-08-02 | 2017-03-01 | Ignyta, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
PL3122358T3 (pl) | 2014-03-26 | 2021-06-14 | Astex Therapeutics Ltd. | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu |
CA2943687C (en) | 2014-03-26 | 2024-02-13 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
KR20170137717A (ko) | 2015-02-19 | 2017-12-13 | 바이오클린 테라퓨틱스, 인크. | 암의 치료를 위한 방법, 조성물, 및 키트 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
-
2010
- 2010-04-30 GB GB201007286A patent/GB201007286D0/en not_active Ceased
-
2011
- 2011-04-19 JO JOP/2011/0133A patent/JO3366B1/ar active
- 2011-04-27 TW TW100114665A patent/TWI545122B/zh active
- 2011-04-28 DK DK16207610.3T patent/DK3178818T3/da active
- 2011-04-28 CR CR20180339A patent/CR20180339A/es unknown
- 2011-04-28 ES ES19175481T patent/ES2899937T3/es active Active
- 2011-04-28 CN CN201510087109.8A patent/CN104725362B/zh active Active
- 2011-04-28 HU HUE16207610A patent/HUE045893T2/hu unknown
- 2011-04-28 MX MX2012012414A patent/MX2012012414A/es active IP Right Grant
- 2011-04-28 RS RSP20191045 patent/RS59196B1/sr unknown
- 2011-04-28 EP EP16207610.3A patent/EP3178818B1/en active Active
- 2011-04-28 LT LTEP11724710.6T patent/LT2563775T/lt unknown
- 2011-04-28 LT LTEP16207610.3T patent/LT3178818T/lt unknown
- 2011-04-28 DK DK11724710.6T patent/DK2563775T3/en active
- 2011-04-28 PL PL16207610T patent/PL3178818T3/pl unknown
- 2011-04-28 CN CN201180021785.5A patent/CN102858765B/zh active Active
- 2011-04-28 PT PT117247106T patent/PT2563775T/pt unknown
- 2011-04-28 AP AP2012006490A patent/AP3210A/xx active
- 2011-04-28 AR ARP110101476 patent/AR080982A1/es active IP Right Grant
- 2011-04-28 AU AU2011247047A patent/AU2011247047B2/en active Active
- 2011-04-28 SI SI201132013T patent/SI3590934T1/sl unknown
- 2011-04-28 HU HUE11724710A patent/HUE033702T2/en unknown
- 2011-04-28 MY MYPI2016001863A patent/MY191669A/en unknown
- 2011-04-28 RS RS20211397A patent/RS62570B1/sr unknown
- 2011-04-28 EA EA201500278A patent/EA028599B1/ru unknown
- 2011-04-28 MY MYPI2012004699A patent/MY189427A/en unknown
- 2011-04-28 BR BR112012027509-7A patent/BR112012027509B1/pt active IP Right Grant
- 2011-04-28 PL PL11724710T patent/PL2563775T3/pl unknown
- 2011-04-28 RS RS20170353A patent/RS55863B1/sr unknown
- 2011-04-28 SG SG2012078085A patent/SG184966A1/en unknown
- 2011-04-28 IN IN2591MUN2012 patent/IN2012MN02591A/en unknown
- 2011-04-28 ES ES16207610T patent/ES2742409T3/es active Active
- 2011-04-28 CA CA2796204A patent/CA2796204C/en active Active
- 2011-04-28 WO PCT/GB2011/050851 patent/WO2011135376A1/en active Application Filing
- 2011-04-28 KR KR1020187023217A patent/KR101933843B1/ko active IP Right Grant
- 2011-04-28 JP JP2013506755A patent/JP5639261B2/ja active Active
- 2011-04-28 EA EA201291143A patent/EA023222B8/ru unknown
- 2011-04-28 SG SG10201708578QA patent/SG10201708578QA/en unknown
- 2011-04-28 MX MX2015012476A patent/MX365702B/es unknown
- 2011-04-28 ES ES11724710.6T patent/ES2621461T3/es active Active
- 2011-04-28 SI SI201131112A patent/SI2563775T1/sl unknown
- 2011-04-28 EP EP19175481.1A patent/EP3590934B1/en active Active
- 2011-04-28 EP EP11724710.6A patent/EP2563775B1/en active Active
- 2011-04-28 SI SI201131755T patent/SI3178818T1/sl unknown
- 2011-04-28 HR HRP20211675TT patent/HRP20211675T1/hr unknown
- 2011-04-28 DK DK19175481.1T patent/DK3590934T3/da active
- 2011-04-28 PT PT191754811T patent/PT3590934T/pt unknown
- 2011-04-28 PL PL19175481T patent/PL3590934T3/pl unknown
- 2011-04-28 NZ NZ602726A patent/NZ602726A/en unknown
- 2011-04-28 US US13/643,741 patent/US8895601B2/en active Active
- 2011-04-28 LT LTEP19175481.1T patent/LT3590934T/lt unknown
- 2011-04-28 PT PT16207610T patent/PT3178818T/pt unknown
- 2011-04-28 ME MEP-2013-123A patent/ME01825B/me unknown
- 2011-04-28 HU HUE19175481A patent/HUE056999T2/hu unknown
- 2011-04-28 KR KR1020127031310A patent/KR101889565B1/ko active Protection Beyond IP Right Term
-
2012
- 2012-10-22 IL IL222600A patent/IL222600A/en active IP Right Grant
- 2012-10-30 CL CL2012003048A patent/CL2012003048A1/es unknown
- 2012-11-13 CR CR20120576A patent/CR20120576A/es unknown
- 2012-11-29 EC ECSP12012318 patent/ECSP12012318A/es unknown
-
2014
- 2014-10-02 US US14/505,020 patent/US9464071B2/en active Active
-
2016
- 2016-04-28 US US15/141,061 patent/US9850228B2/en active Active
-
2017
- 2017-04-18 AU AU2017202512A patent/AU2017202512B2/en active Active
- 2017-11-13 US US15/810,521 patent/US10519137B2/en active Active
-
2019
- 2019-08-09 CY CY20191100858T patent/CY1121882T1/el unknown
- 2019-10-25 US US16/663,579 patent/US20200131153A1/en not_active Abandoned
-
2021
- 2021-10-20 US US17/451,601 patent/US20220135544A1/en active Pending
- 2021-11-23 CY CY20211101014T patent/CY1124928T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500271B (it) | Inibitori di neprilisina | |
CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
BR112012028556A2 (pt) | Indóis | |
DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
DK3225404T3 (da) | Fluidpatron | |
CR20130111A (es) | Triazina-oxidiazoles | |
DE10170954T8 (de) | Mikrowellendruckgarer | |
BR112013016154A2 (pt) | inibidores de faah | |
DE112011104226A5 (de) | Käfigmutter | |
DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
DE112011102080A5 (de) | Kupplungszentralausrücker | |
DE112011101226A5 (de) | Linearwegmesssystem | |
DK2442899T3 (da) | Rotorskive | |
DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
DE112011102711A5 (de) | Hydrostataktor | |
DK2448659T3 (da) | Rotorskive | |
DK2447426T3 (da) | Vaske-WC | |
DE102010019119B8 (de) | Cuttermesser | |
BR112013014148A2 (pt) | inibidores de corrosão | |
DE112010005518A5 (de) | Dichtungsmanchette | |
DE102010038420A8 (de) | Reinigungungsvorrichtung | |
DK2596072T3 (da) | Bor-forbindelses-suspension | |
DE102010035554B8 (de) | Fußtüröffner | |
CO6801789A2 (es) | N-hetarilmetil pirazolilcarboxamidas | |
DE112011101796A5 (de) | Redoxakkumulatoranlage |